Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects-Reference-Cited by-同舟云学术

Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects

Published:2018-08 Issue:8 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rodvold Keith A.¹,Gotfried Mark H.¹²,Chugh Rakesh³,Gupta Mugdha³,Patel Anasuya⁴,Chavan Rajesh⁴,Yeole Ravindra³,Friedland H. David⁵,Bhatia Ashima³

Affiliation:

1. University of Illinois at Chicago, Chicago, Illinois, USA

2. Pulmonary Associates, PA, Phoenix, Arizona, USA

3. Wockhardt Ltd., Mumbai, India

4. Wockhardt Ltd., Aurangabad, India

5. Wockhardt's Morton Grove Pharmaceuticals Inc., Morton Grove, Illinois, USA

Abstract

WCK 5222 is a combination of cefepime and the novel β-lactam enhancer zidebactam being developed for the treatment of serious Gram-negative bacterial infections. The objective of this study was to compare plasma (total), epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of cefepime and zidebactam in healthy adult subjects.

Funder

Wockhardt

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00682-18

Reference40 articles.

1. What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles

2. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015

3. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases